St. Louis Encephalitis Virus

Overview

St. Louis encephalitis virus (SLEV) is a mosquito-borne flavivirus (family Flaviviridae) endemic to the Americas and a significant cause of epidemic viral encephalitis. Maintained in an enzootic cycle between wild birds and Culex mosquitoes, SLEV sporadically spills over into human populations, where it can cause a spectrum of disease ranging from mild febrile illness to severe neuroinvasive disease (meningitis, encephalitis, and acute flaccid paralysis). A hallmark of SLEV is its pronounced age-related severity, with older adults experiencing significantly higher rates of encephalitis and mortality. Despite the availability of effective veterinary vaccines for related flaviviruses, no human vaccine or specific antiviral therapy exists for SLEV. Its re-emergence in recent years, including outbreaks in the United States and Argentina, underscores its persistent public health threat.

Basic Characteristics of SLEV

SLEV is an enveloped, single-stranded, positive-sense RNA virus with a genome approximately 11 kb in length. The viral particle has a spherical morphology, with a diameter of 40–50 nm, consisting of a lipid envelope derived from the host cell membrane, a nucleocapsid composed of capsid (C) protein, and a genome enclosed within the nucleocapsid. The viral envelope contains two glycoproteins: envelope (E) protein and membrane (M) protein, which play critical roles in viral entry and pathogenesis. The SLEV genome encodes a single polyprotein that is cleaved by viral and host proteases into three structural proteins (C, prM/M, E) and seven non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) during viral replication. SLEV is primarily transmitted by mosquitoes of the genus Culex, with Culex pipiens, Culex quinquefasciatus, and Culex tarsalis serving as the main vectors in different regions of the Americas. Birds act as the primary reservoir hosts, particularly migratory birds, which facilitate the geographic spread of the virus; humans and other mammals are incidental hosts that do not contribute to viral transmission. The virus can overwinter in mosquito-bird cycles, leading to seasonal outbreaks typically occurring in summer and early fall, when mosquito activity is highest.

Fugre 1. Structure and assembly of SLEV E. (Luca V C, et al., 2013)

Host-Virus Interactions

SLEV interacts with numerous host cell molecules and pathways during infection, utilizing host factors to facilitate its replication and evading host immune responses to establish infection. These interactions are critical for viral pathogenesis and represent potential targets for the development of antiviral therapies.

Host Factors Utilized by SLEV

SLEV relies on several host cell factors to complete its life cycle. As mentioned earlier, LDLR family members and HSPGs act as receptors/attachment factors for viral entry, facilitating the initial binding and internalization of the virus into host cells. Host cell chaperone proteins, such as heat shock protein 70 (HSP70) and glucose-regulated protein 78 (GRP78), assist in the folding and maturation of viral proteins, particularly the E protein, which is essential for viral entry and assembly. Host cell proteases, including furin and signal peptidases, are critical for the processing of the viral polyprotein into mature structural and non-structural proteins. Additionally, SLEV utilizes the host cell's cytoskeletal network (e.g., microtubules and actin filaments) for the transport of viral components within the cell, as well as for viral assembly and release. The host cell's lipid metabolism pathways are also hijacked by SLEV, as the virus requires cholesterol and other lipids for the formation of viral replication complexes and the assembly of the viral envelope.

Epidemiology and Transmission Cycle

Pathological Changes	Details
Enzootic Cycle	SLEV is maintained in a bird-mosquito-bird cycle. Primary Vectors: Mosquitoes of the Culex genus, primarily Cx. pipiens and Cx. quinquefasciatus in eastern North America, Cx. tarsalis in western North America, and Cx. nigripalpus in Florida. Amplifying Hosts: Wild birds, especially passerines (sparrows, finches, cardinals), develop high-titer viremia sufficient to infect feeding mosquitoes without suffering severe illness.
Spillover to Humans and Other Mammals	Humans, horses, and other mammals are dead-end hosts. Spillover occurs when infected bridge vectors feed on these hosts. Urban and peri-urban outbreaks are often linked to Cx. pipiens complex mosquitoes breeding in polluted water.
Risk Factors and Geographic Distribution	SLEV is found from Canada to Argentina. In the U.S., major outbreaks have occurred in the Midwest, Texas, Florida, and California. Key risk factors include: Age: The single most important risk factor for severe disease. Adults over 60 years have a 10-30 times higher risk of encephalitis and death compared to younger adults. Outdoor Exposure: Occupational or recreational activities during peak mosquito hours. Environmental Conditions: Warm temperatures, rainfall patterns, and drought conditions that affect mosquito abundance and bird-mosquito contact rates.

Prevention, Control, and Research Outlook

Vector Control: The primary public health response during outbreaks (larval source reduction, adulticiding).
Surveillance: Integrated monitoring of mosquito pools, dead birds, and sentinel chickens provides early warning of increased viral activity.
Vaccines: No human vaccine exists. An inactivated mouse brain-derived vaccine was used in the 1970s for lab workers but is not available. Research on chimeric (e.g., YF17D backbone), DNA, or mRNA vaccines is ongoing but not a high priority due to the sporadic nature of outbreaks.
Antivirals: No licensed therapy. Broad-spectrum nucleoside analogs (e.g., Galidesivir) and host-targeting agents are in preclinical stages for flaviviruses.

Conclusions

St. Louis encephalitis virus remains a prototypical and persistent neurotropic arbovirus, whose public health impact is characterized by severe, focal outbreaks disproportionately affecting the elderly. While its incidence has been reduced in the WNV era, its endemic maintenance and proven epidemic potential necessitate continued vigilance. The molecular dissection of its lifecycle—from E-mediated entry and NS5-driven replication to NS1/NS4-mediated immune evasion—has unveiled a suite of potential targets for antiviral development. A comprehensive strategy combining enhanced surveillance, vector management, and targeted research into pathogenesis and therapeutics is essential to mitigate the burden of this historically significant and still-relevant pathogen.

Reference

Luca V C, Nelson C A, Fremont D H. Structure of the St. Louis encephalitis virus postfusion envelope trimer. Journal of virology, 2013, 87(2): 818-828.

Reagent Solutions

Anti-Saint louis encephalitis virus Antibody

Target	Cat. No.	Product Name	Host	Isotype	Application
SLEV NS1	CABT-CS262	Magic™ Mouse anti-Saint Louis Encephalitis Virus NS1 monoclonal antibody, clone MN051	Mouse	IgG2a	ELISA(cap), LFIA	Inquiry
SLEV NS1	CABT-CS263	Magic™ Mouse anti-Saint Louis Encephalitis Virus NS1 monoclonal antibody, clone MN052	Mouse	IgG1	ELISA(det), LFIA	Inquiry
SLEV	DCABY-833	Anti-Saint louis encephalitis virus Monoclonal antibody, Clone 7c7d-2	Mouse	IgG2a	ELISA, IF	Inquiry
SLEV Env	CABT-NS1226	Human Anti-St. Louis Encephalitis Virus Env Monoclonal Antibody, clone 6B6C-1	Human	IgG1	WB, IP, ELISA	Inquiry

Recombinant St. Louis encephalitis virus Antigens

Target	Cat. No.	Product Name	Host
SLEV	DAGA-3071	Recombinant St. Louis encephalitis virus NS1 [His]	HEK293	Inquiry

Inquiry Basket

Loading ......

Inquiry